Zomedica Reports Q3 2025 Financial Results: Revenue Increases 16% to $8.1 Million, Achieving 67% Gross Margins and $54 Million in Available Liquidity for Growth Initiatives

Written by Emily J. Thompson, Senior Investment Analyst

Source: Yahoo Finance

Updated: Nov 04 2025

0mins

Source: Yahoo Finance

Record Revenue Achievement: Zomedica Corp. reported its highest quarterly revenue ever at $8.1 million for Q3 2025, marking a 16% increase year-over-year and achieving record revenue for the 19th consecutive quarter.
Growth in Product Segments: The Diagnostics segment saw a significant 51% growth, driven by the adoption of the TRUFORMA diagnostic platform, while the Therapeutic Device segment grew by 3%. Additionally, a new Development Services segment contributed $0.7 million in revenue.
International Expansion: Zomedica's international sales increased by 16% compared to Q3 2024, bolstered by new distribution agreements in the UK and strengthened partnerships in the Netherlands and Canada.
Cost Management and Profitability Outlook: The company successfully reduced operating expenses by $0.5 million in Q3 2025, leading to a net loss decrease of 9% to $6.1 million, and is optimistic about reaching cash flow breakeven and profitability in the future.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.